Quick Ratio (Acid-Test): 1.08
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.08 is in line with its 5-year average of 1.17, around the middle of its 5-year range (0.83–1.63).
As of Friday, June 26, 2026. 0.05% below its 12-month average of 1.08.
DGX Quick Ratio
Reported quarterly quick ratio; no daily interpolation.
DGX Average Quick Ratio (Acid-Test) Chart
DGX Current vs Average Quick Ratio (Acid-Test) Chart
DGX Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.08
QUICK RATIO (ACID-TEST) AVG TTM
1.08
QUICK RATIO (ACID-TEST) AVG 3Y
1.05
QUICK RATIO (ACID-TEST) AVG 5Y
1.17
QUICK RATIO (ACID-TEST) AVG 10Y
1.19
QUICK RATIO (ACID-TEST) AVG 15Y
1.16
QUICK RATIO (ACID-TEST) AVG 20Y
1.16
CURRENT VS TTM AVG
-0.05%
CURRENT VS 3Y AVG
+2.80%
CURRENT VS 5Y AVG
-8.33%
CURRENT VS 10Y AVG
-9.67%
CURRENT VS 15Y AVG
-7.36%
CURRENT VS 20Y AVG
-7.54%
DGX Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $22.83B | 1.08 | 1.08 | 1.05 | 1.17 |
| BioNTech SE (BNTX)vs › | $22.76B | 7.49 | 7.42 | 7.84 | 6.36 |
| United Therapeutics Corporation (UTHR)vs › | $23.07B | 6.28 | 5.66 | 6.29 | 6.48 |
| Moderna, Inc. (MRNA)vs › | $23.71B | 3.22 | 3.42 | 3.19 | 2.63 |
| Labcorp Holdings Inc. (LH)vs › | $21.83B | 1.23 | 1.27 | 1.23 | 1.37 |
| Incyte Corporation (INCY)vs › | $21.48B | 3.25 | 2.59 | 3.09 | 3.29 |
| Waters Corporation (WAT)vs › | $24.57B | 1.27 | 1.39 | 1.50 | 1.54 |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | 0.81 | 0.77 | 0.77 | 0.79 |
| STERIS plc (STE)vs › | $20.52B | 1.54 | 1.46 | 1.73 | 1.65 |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 4.89 | 4.70 | 4.39 | 4.08 |
Liquidity Comparison
Quick Ratio
1.08
Excludes inventory
Current Ratio
1.04
Includes inventory
Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The quick ratio (acid-test) for DGX stock is 1.08.
- Is Quest Diagnostics Incorporated's quick ratio (acid-test) high or low?
- The quick ratio (acid-test) of 1.08 is in line with its 5-year average of 1.17, around the middle of its 5-year range (0.83–1.63).
- What is the TTM average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The TTM average quick ratio (acid-test) for DGX stock is 1.08.
- What is the 3Y average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The 3Y average quick ratio (acid-test) for DGX stock is 1.05.
- What is the 5Y average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The 5Y average quick ratio (acid-test) for DGX stock is 1.17.
- What is the 10Y average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The 10Y average quick ratio (acid-test) for DGX stock is 1.19.
- What is the 15Y average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The 15Y average quick ratio (acid-test) for DGX stock is 1.16.
- What is the 20Y average quick ratio (acid-test) for Quest Diagnostics Incorporated (DGX)?
- The 20Y average quick ratio (acid-test) for DGX stock is 1.16.
DGX Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-03-31 | 1.08 |
| 2025-12-31 | 0.96 |
| 2025-09-30 | 1.04 |
| 2025-06-30 | 0.99 |
| 2025-03-31 | 1.31 |
| 2024-12-31 | 1.02 |
| 2024-09-30 | 1.17 |
| 2024-06-30 | 0.91 |
| 2024-03-31 | 0.89 |
| 2023-12-31 | 1.20 |
| 2023-09-30 | 1.01 |
| 2023-06-30 | 0.83 |
| 2023-03-31 | 1.20 |
| 2022-12-31 | 1.10 |
| 2022-09-30 | 1.34 |
| 2022-06-30 | 1.42 |
| 2022-03-31 | 1.34 |
| 2021-12-31 | 1.44 |
| 2021-09-30 | 1.51 |
| 2021-06-30 | 1.26 |
| 2021-03-31 | 1.63 |
| 2020-12-31 | 1.60 |
| 2020-09-30 | 1.32 |
| 2020-06-30 | 1.21 |
| 2020-03-31 | 1.27 |
| 2019-12-31 | 1.19 |
| 2019-09-30 | 0.83 |
| 2019-06-30 | 0.77 |
| 2019-03-31 | 0.74 |
| 2018-12-31 | 0.87 |
| 2018-09-30 | 1.09 |
| 2018-06-30 | 1.05 |
| 2018-03-31 | 1.14 |
| 2017-12-31 | 1.15 |
| 2017-09-30 | 1.37 |
| 2017-06-30 | 1.55 |
| 2017-03-31 | 1.50 |
| 2016-12-31 | 1.48 |
| 2016-09-30 | 1.49 |
| 2016-06-30 | 1.29 |
| 2016-03-31 | 1.29 |
| 2015-12-31 | 1.21 |
| 2015-09-30 | 1.38 |
| 2015-06-30 | 1.14 |
| 2015-03-31 | 1.09 |
| 2014-12-31 | 0.87 |
| 2014-09-30 | 1.22 |
| 2014-06-30 | 1.11 |
| 2014-03-31 | 1.17 |
| 2013-12-31 | 1.14 |
| 2013-09-30 | 1.08 |
| 2013-06-30 | 1.07 |
| 2013-03-31 | 1.13 |
| 2012-12-31 | 1.40 |
| 2012-09-30 | 1.29 |
| 2012-06-30 | 1.05 |
| 2012-03-31 | 0.94 |
| 2011-12-31 | 0.84 |
| 2011-09-30 | 0.74 |
| 2011-06-30 | 0.70 |
| 2011-03-31 | 1.43 |
| 2010-12-31 | 1.26 |
| 2010-09-30 | 1.29 |
| 2010-06-30 | 1.56 |
| 2010-03-31 | 1.45 |
| 2009-12-31 | 1.50 |
| 2009-09-30 | 1.40 |
| 2009-06-30 | 1.23 |
| 2009-03-31 | 1.10 |
| 2008-12-31 | 1.14 |
| 2008-09-30 | 1.17 |
| 2008-06-30 | 1.17 |
| 2008-03-31 | 1.15 |
| 2007-12-31 | 0.99 |
| 2007-09-30 | 1.13 |
| 2007-06-30 | 1.14 |
| 2007-03-31 | 0.74 |
| 2006-12-31 | 0.97 |
| 2006-09-30 | 0.99 |
| 2006-06-30 | 1.04 |
| 2006-03-31 | 1.00 |
| 2005-12-31 | 0.90 |
| 2005-09-30 | 0.90 |
| 2005-06-30 | 1.14 |
| 2005-03-31 | 1.03 |
| 2004-12-31 | 0.82 |
| 2004-09-30 | 1.33 |
| 2004-06-30 | 1.26 |
| 2004-03-31 | 1.51 |
| 2003-12-31 | 1.28 |
| 2003-09-30 | 1.34 |
| 2003-06-30 | 1.32 |
| 2003-03-31 | 1.25 |
| 2002-12-31 | 1.20 |
| 2002-09-30 | 1.01 |
| 2002-06-30 | 0.93 |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis